Biodesix (BDSX) AI Stock Analysis

• Market Cap: $53.84M
• Dividend Yield: N/A
• Average Volume (3M): 107.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.94
• Revenue Growth: 25.70%
• EPS Growth: 39.25%
• Country: US
• Employees: 273
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -1.60
• Shares Outstanding: 8,000,000
• 10 Day Avg. Volume: 48,205
• 30 Day Avg. Volume: 107,552
• PEG Ratio: 0.10
• Price to Book (P/B): 9.50
• Price to Sales (P/S): 2.78
• P/FCF Ratio: -3.82
• Enterprise Value/Market Cap: 1.72
• Enterprise Value/Revenue: 1.21
• Enterprise Value/Gross Profit: 1.54
• Enterprise Value/Ebitda: -3.13
• 1Y Price Target: $95.58
• Price Target Upside: 1337.29% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 41 Neutral
• Price Target: $5.50 ▼(-17.29% Downside)

Biodesix faces significant financial challenges with high leverage and negative profitability, reflected in a low valuation score. Technical indicators suggest bearish momentum, further impacting the stock's outlook. While there is potential for improvement due to strong gross margins and strategic initiatives, these have yet to translate into financial stability.

Positive Factors

Revenue Growth

The consistent revenue growth indicates strong market demand and successful product adoption, which can lead to increased market share and financial stability over time.

Strategic Partnership

The expanded partnership with Bio-Rad enhances Biodesix's technological capabilities and market reach, potentially leading to new revenue streams and strengthening its competitive position in oncology diagnostics.

Improved Gross Margins

Improved gross margins reflect operational efficiency and pricing power, which can enhance profitability and provide a buffer against cost fluctuations, supporting long-term financial health.

Negative Factors

High Leverage

High leverage increases financial risk and limits flexibility, potentially impacting the company's ability to invest in growth opportunities and weather economic downturns.

Negative Cash Flow

Negative cash flow growth suggests challenges in sustaining operations and funding future growth, which could strain resources and necessitate external financing.

Increased Operating Expenses

Rising operating expenses without corresponding revenue growth can pressure margins and profitability, potentially hindering the company's ability to achieve financial stability.

Biodesix Business Overview & Revenue Model

Company Description

Biodesix, Inc. (BDSX) is a biotechnology company focused on developing and commercializing diagnostic tests for lung cancer and other diseases. The company operates in the healthcare sector, utilizing advanced genomic and proteomic technologies to provide insights that help physicians make informed treatment decisions. Biodesix's core products include non-invasive blood tests that analyze biomarkers to predict patient responses to therapies, thereby enabling personalized treatment strategies for oncology patients.

How the Company Makes Money

Biodesix generates revenue primarily through the sale of its diagnostic tests, which are offered to medical institutions, oncology clinics, and healthcare providers. The company's revenue model is centered around test reimbursements from insurance companies and healthcare payers, allowing them to capture a portion of the revenue generated from patient testing. In addition to test sales, Biodesix may also engage in partnerships with pharmaceutical companies for companion diagnostics, which can further enhance revenue. The company benefits from strategic collaborations and agreements that expand its market reach and facilitate access to new technologies and patient populations, thereby contributing to its overall earnings.

Biodesix Financial Statement Overview

Summary

Biodesix is experiencing revenue growth, but profitability and cash flow challenges persist. High leverage and negative equity returns indicate financial instability, while strong gross margins suggest potential for improvement if cost management is addressed. The company needs to focus on reducing debt and improving operational efficiency to enhance financial health.

Income Statement

Biodesix shows a consistent increase in revenue with a TTM growth rate of 2.81%, indicating positive momentum. However, the company struggles with profitability, as evidenced by negative net profit margins and EBIT margins. The gross profit margin is strong at 78.77% TTM, but the persistent negative net income highlights ongoing challenges in cost management and operational efficiency.

Balance Sheet

The balance sheet reveals significant leverage with a TTM debt-to-equity ratio of 63.39, indicating high financial risk. The return on equity is negative, reflecting losses and insufficient returns for shareholders. The equity ratio is low, suggesting limited asset backing by equity, which could pose risks in financial stability.

Cash Flow

Cash flow analysis shows a negative free cash flow growth rate of -30.86% TTM, indicating deteriorating cash generation. The operating cash flow to net income ratio is negative, highlighting cash flow challenges. However, the free cash flow to net income ratio is slightly positive, suggesting some ability to cover net losses with free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	76.56M	71.32M	49.09M	38.21M	54.51M	45.56M
Gross Profit	60.30M	55.75M	36.08M	24.06M	23.99M	23.56M
EBITDA	-29.63M	-29.22M	-37.10M	-53.78M	-35.47M	-20.84M
Net Income	-41.08M	-42.93M	-52.15M	-65.45M	-43.16M	-31.35M
Balance Sheet
Total Assets	87.74M	97.24M	99.10M	92.91M	76.10M	121.07M
Cash, Cash Equivalents and Short-Term Investments	20.73M	26.25M	26.28M	43.09M	32.71M	62.13M
Total Debt	72.14M	61.98M	60.69M	31.85M	10.01M	27.77M
Total Liabilities	86.60M	76.37M	94.52M	72.30M	56.37M	79.90M
Stockholders Equity	1.14M	20.88M	4.58M	20.61M	19.73M	41.17M
Cash Flow
Free Cash Flow	-31.30M	-51.88M	-45.93M	-48.51M	-30.77M	-23.54M
Operating Cash Flow	-29.94M	-48.65M	-22.87M	-44.97M	-28.22M	-21.37M
Investing Cash Flow	-1.40M	-3.44M	-23.06M	-3.53M	-2.55M	-2.93M
Financing Cash Flow	9.85M	52.05M	29.13M	58.88M	1.26M	81.13M

Biodesix Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDSX, the sentiment is Negative. The current price of 6.65 is below the 20-day moving average (MA) of 7.13, below the 50-day MA of 7.81, and below the 200-day MA of 10.57, indicating a bearish trend. The MACD of -0.35 indicates Positive momentum. The RSI at 42.91 is Neutral, neither overbought nor oversold. The STOCH value of 42.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BDSX.

Biodesix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	―	$33.28M	-17.24	-14.76%	―	27.05%	55.03%
BNR	―	$140.58M	-6.97	-22.66%	―	5.33%	75.52%
SERA	―	$142.73M	―	-44.24%	―	0.93%	13.99%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VNRX	―	$50.60M	-1.74	―	―	35.10%	39.15%
BDSX	―	$53.84M	-1.20	-219.68%	―	25.70%	39.25%
CHEK	―	$11.37M	―	―	―	―	―

Biodesix Corporate Events

Biodesix Regains Nasdaq Compliance with Bid Price

On September 26, 2025, Biodesix, Inc. announced that it has regained compliance with the Nasdaq’s minimum bid price requirement, ensuring its continued listing on The Nasdaq Global Market. This follows a previous notification in March 2025, when the company’s stock had fallen below the $1.00 per share minimum, but has now maintained a closing bid price of at least $1.00 for ten consecutive business days, resolving the issue.

The most recent analyst rating on (BDSX) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Biodesix stock, see the BDSX Stock Forecast page.

Biodesix Implements Reverse Stock Split on September 15

On September 15, 2025, Biodesix, Inc. implemented a one-for-twenty reverse stock split of its common stock, following approval from its Board of Directors and stockholders earlier in May 2025. This move, effective as of September 15, 2025, aims to adjust the trading price of its common stock, with no fractional shares issued; instead, stockholders will receive cash for fractional entitlements. Additionally, on September 12, 2025, the company filed a Certificate of Elimination to remove provisions related to its Series A Non-Voting Convertible Preferred Stock, marking a strategic shift in its stock structure.

The most recent analyst rating on (BDSX) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Biodesix stock, see the BDSX Stock Forecast page.

Biodesix Announces Reverse Stock Split Effective Sept 15

On September 11, 2025, Biodesix, Inc. announced a one-for-twenty reverse stock split of its common stock, effective September 15, 2025. This move, approved by stockholders in May 2025, will reduce the number of outstanding shares from approximately 156 million to 8 million, while maintaining the same percentage ownership for stockholders, except for fractional shares which will be compensated in cash. The reverse stock split will also adjust the number of shares and exercise prices for the company’s outstanding equity awards and warrants, aiming to enhance the company’s stock market positioning.

The most recent analyst rating on (BDSX) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Biodesix stock, see the BDSX Stock Forecast page.

Biodesix, Inc. Reports Strong Q2 2025 Growth

Biodesix, Inc. Reports Strong Revenue Growth Amidst Challenges

Biodesix Reports Strong Q2 2025 Revenue Growth

Biodesix, Inc. is a diagnostic solutions company specializing in lung disease diagnostics and personalized care, operating within the healthcare sector. In its latest earnings report, Biodesix announced a 12% increase in revenue for the second quarter of 2025, reaching $20 million, and a gross profit margin improvement to 80%. The company also reaffirmed its full-year revenue guidance of $80-85 million. Key financial highlights include a significant 53% growth in Development Services revenue and an increase in lung diagnostic testing revenue by 8%. The company expanded its sales team by 21% and saw a notable rise in digital ordering and primary care physician engagement. Despite a net loss of $11.5 million, Biodesix remains optimistic about achieving Adjusted EBITDA positivity by the fourth quarter, driven by sales team expansion and operational effectiveness. Looking forward, Biodesix is confident in its growth trajectory and aims for sustainable long-term success, supported by its strategic initiatives and market expansion efforts.